Elicera Therapeutics AB (OSTO:ELIC) ROCE % : -101.11% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Elicera Therapeutics AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -101.11%.

Elicera Therapeutics AB ROCE % Historical Data

The historical data trend for Elicera Therapeutics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB ROCE % Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-31.60

-52.04

-42.00

-45.41

-66.34

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial												-44.87	-28.62	-60.98	-84.23	-101.11

Elicera Therapeutics AB ROCE % Calculation

Elicera Therapeutics AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-16.322	/	( ( (46.308 - 13.509)	+	(30.18 - 13.772) )	/ 2 )
	=	-16.322	/	( (32.799	+	16.408)	/ 2 )
	=	-16.322	/	24.6035
	=	-66.34 %

Elicera Therapeutics AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-18.988	/	( ( (28.151 - 7)	+	(30.18 - 13.772) )	/ 2 )
	=	-18.988	/	( ( 21.151	+	16.408 )	/ 2 )
	=	-18.988	/	18.7795
	=	-101.11 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Elicera Therapeutics AB (OSTO:ELIC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Elicera Therapeutics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines